US Tariff Threats Cast Shadow Over Nearly Finalized India Trade Deal

U.S. Ambassador to India Sergio Gor recently stated that the India-U.S. trade agreement is on the verge of finalization, with "almost everything" agreed upon "in principle." However, two recent U.S. initiatives have raised new tensions, potentially jeopardizing the deal.

The first is the Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, a bipartisan bill backed by President Donald Trump and overwhelmingly passed by the Senate (86-11) in early August. The bill proposes 500 percent tariffs on all goods imported from Russia and 100 percent tariffs on goods from the five largest importers of Russian crude oil or natural gas by volume. Market analysts identify India as the second-largest buyer of Russian crude oil in July 2026, with imports valued at over $7.3 billion, representing about 37 percent of Russia's global exports. India would face penal tariffs under this provision.

The second development is Trump's proposal to impose 100 percent tariffs on generic medicines starting in 2028 unless exporting firms shift production to the U.S. This would significantly affect India's pharmaceutical industry, as the U.S. is its largest export market for generic drugs.

Analyst Biswajit Dhar notes that these measures could torpedo the trade deal even before it is formalized, as they introduce new friction that undermines the promise of deeper economic cooperation. The House of Representatives is expected to take up the sanctions bill in early September.

Why This Matters

The potential collapse of the India-U.S. trade deal would disrupt one of the most significant bilateral economic partnerships under negotiation, affecting industries from pharmaceuticals to energy.
U.S. measures targeting Russian oil importers directly penalize India's energy strategy, which relies heavily on discounted Russian crude, and could force a costly rebalancing of energy sources.
For American consumers, tariffs on generic drugs could increase healthcare costs, as India is a major supplier of affordable medications.

Background

The India-U.S. trade relationship has grown significantly in recent decades, with both sides seeking a comprehensive agreement since 2018. The current negotiations aim to lower tariffs and deepen cooperation, but have been repeatedly delayed by disagreements over market access, intellectual property, and geopolitical alignment. India's continued purchase of Russian oil following the Ukraine invasion has been a persistent point of friction in Washington, leading to bipartisan efforts to penalize such imports. The Trump administration's "America First" policy has also targeted pharmaceutical supply chains, aiming to reduce reliance on foreign production.

Key Perspectives

U.S. Administration and Senate Backers: Argue that the sanctions bill is necessary to starve Russia of war revenue and that penalizing countries enabling sanctions evasion is a legitimate enforcement tool. The generic drug tariff is framed as a national security and public health imperative to secure domestic manufacturing capacity. Indian Government and Industry: Face a dilemma: comply with U.S. demands on Russian oil and pharmaceutical reshoring would impose severe economic costs, while defying them risks losing preferential trade access. The Indian pharmaceutical sector, which depends on the U.S. market, would be especially hard hit by the proposed drug tariffs. Critics and Skeptics: Contend that the punitive measures undermine strategic cooperation and may backfire. Penalizing India for Russian oil purchases could push New Delhi closer to Moscow and Beijing, weakening the U.S.-led Indo-Pacific strategy. The drug tariff, critics say, may increase U.S. healthcare costs without guaranteed reshoring.

What to Watch

The House of Representatives' vote on the Lindsey O. Graham Sanctioning Russia and Iran Act in September.
Whether U.S. negotiators offer exemptions or phase-in periods for India in the trade deal.
India's official response and any retaliatory tariff threats if the measures pass.
The reaction of U.S. pharmaceutical companies to the generic drug tariff proposal—some may support reshoring incentives but oppose mandatory tariffs.

ZOTPAPER